CL2022000330A1 - Composición farmacéutica que contiene un agente antifúngico como ingrediente activo - Google Patents
Composición farmacéutica que contiene un agente antifúngico como ingrediente activoInfo
- Publication number
- CL2022000330A1 CL2022000330A1 CL2022000330A CL2022000330A CL2022000330A1 CL 2022000330 A1 CL2022000330 A1 CL 2022000330A1 CL 2022000330 A CL2022000330 A CL 2022000330A CL 2022000330 A CL2022000330 A CL 2022000330A CL 2022000330 A1 CL2022000330 A1 CL 2022000330A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- active ingredient
- luliconazole
- composition containing
- antifungal agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona una técnica que permite que una composición farmacéutica, preferiblemente para uso externo, que contiene luliconazol o similar, contenga luliconazol o similar en una alta concentración, y suprime la precipitación del mismo con el tiempo. La presente invención usa un polietilenglicol que tiene un peso molecular promedio de 380 a 420 representado por una fórmula HOCH2(CH2OCH2)nCH2OH (donde n es un número entero), etanol, alcohol bencílico, ácido láctico, carbonato de propileno y acetona en combinación con el luliconazol o similares.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019148620 | 2019-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022000330A1 true CL2022000330A1 (es) | 2022-10-21 |
Family
ID=74190800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022000330A CL2022000330A1 (es) | 2019-08-13 | 2022-02-08 | Composición farmacéutica que contiene un agente antifúngico como ingrediente activo |
Country Status (12)
Country | Link |
---|---|
US (2) | US10898470B1 (es) |
EP (1) | EP4015042A4 (es) |
JP (1) | JP6888180B1 (es) |
KR (1) | KR20220035954A (es) |
CN (1) | CN114206387A (es) |
AU (1) | AU2020327775B2 (es) |
BR (1) | BR112022002269A2 (es) |
CA (1) | CA3149802A1 (es) |
CL (1) | CL2022000330A1 (es) |
MX (1) | MX2022001601A (es) |
TW (1) | TW202114661A (es) |
WO (1) | WO2021029350A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10898470B1 (en) * | 2019-08-13 | 2021-01-26 | Sato Pharmaceutical Co., Ltd. | Pharmaceutical composition containing antifungal agent as active ingredient |
WO2024024520A1 (ja) * | 2022-07-28 | 2024-02-01 | 花王株式会社 | 外用剤組成物 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5345937B2 (es) | 1974-04-26 | 1978-12-09 | ||
JPS5412723A (en) | 1977-06-29 | 1979-01-30 | Bodysonic Kk | Attentant feeling reproducing unit |
US4162470A (en) | 1977-07-26 | 1979-07-24 | Rca Corporation | Magnetizing apparatus and method for producing a statically converged cathode ray tube and product thereof |
JPS5496659A (en) | 1978-01-17 | 1979-07-31 | Nissan Motor Co Ltd | Automatic transmission gear |
JPS54119654A (en) | 1978-03-08 | 1979-09-17 | Daikou Tetsukou Kk | Method of producing cylindrical fuse |
JPS5938497B2 (ja) | 1980-02-25 | 1984-09-17 | 日立プラント建設株式会社 | 風量制御装置 |
JPH06211651A (ja) | 1993-01-12 | 1994-08-02 | Hisamitsu Pharmaceut Co Inc | 爪白癬治療用組成物 |
JP3803393B2 (ja) | 1994-01-12 | 2006-08-02 | 久光製薬株式会社 | 爪白癬治療用組成物 |
WO1996011710A1 (fr) | 1994-10-13 | 1996-04-25 | Hisamitsu Pharmaceutical Co., Inc. | Preparation externe pour onychomycose |
JP3278738B2 (ja) | 1995-07-08 | 2002-04-30 | 日本農薬株式会社 | 抗真菌剤 |
GB2317615B (en) | 1995-07-08 | 1998-09-02 | Nihon Nohyaku Co Ltd | Antifungal agent compound therefor process for producing the same |
JP4253047B2 (ja) | 1996-09-27 | 2009-04-08 | 杏林製薬株式会社 | 被膜形成性抗真菌剤組成物 |
US6585963B1 (en) | 2001-02-15 | 2003-07-01 | Watson Pharmaceuticals, Inc. | Nail compositions and methods of administering same |
CA2645070C (en) | 2006-03-08 | 2014-02-04 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
WO2007102243A1 (ja) | 2006-03-08 | 2007-09-13 | Nihon Nohyaku Co., Ltd. | 外用の医薬組成物 |
EP2025337B1 (en) | 2006-03-08 | 2014-09-10 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
JP5345937B2 (ja) | 2007-09-05 | 2013-11-20 | 株式会社ポーラファルマ | 抗真菌組成物 |
WO2009031642A1 (ja) | 2007-09-05 | 2009-03-12 | Pola Pharma Inc. | 医薬組成物 |
EP2191828B1 (en) | 2007-09-05 | 2016-08-10 | Pola Pharma Inc. | Antifungal pharmaceutical composition |
EP2395839B1 (en) | 2009-02-13 | 2014-05-07 | Topica Pharmaceuticals, Inc | Anti-fungal formulation |
US10130610B2 (en) | 2009-04-09 | 2018-11-20 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
JP5688406B2 (ja) | 2009-04-09 | 2015-03-25 | 株式会社ポーラファルマ | 抗真菌医薬組成物 |
JP5635075B2 (ja) | 2009-08-25 | 2014-12-03 | 株式会社ポーラファルマ | 抗真菌医薬組成物 |
WO2011155640A1 (en) | 2010-06-11 | 2011-12-15 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
RU2621615C2 (ru) | 2012-09-14 | 2017-06-06 | Пола Фарма Инк. | Фармацевтическая композиция, содержащая луликоназол |
JP2014114249A (ja) | 2012-12-11 | 2014-06-26 | Kanae Technos:Kk | 基剤、及び皮膚外用剤 |
JP5587488B1 (ja) * | 2013-12-12 | 2014-09-10 | 株式会社ポーラファルマ | ルリコナゾールを含有する製剤の評価方法及び指標物質 |
WO2017216722A2 (en) * | 2016-06-13 | 2017-12-21 | Vyome Biosciences Pvt. Ltd. | Synergistic antifungal compositions and methods thereof |
US10898470B1 (en) * | 2019-08-13 | 2021-01-26 | Sato Pharmaceutical Co., Ltd. | Pharmaceutical composition containing antifungal agent as active ingredient |
-
2019
- 2019-12-30 US US16/730,731 patent/US10898470B1/en active Active
-
2020
- 2020-08-04 TW TW109126318A patent/TW202114661A/zh unknown
- 2020-08-07 CA CA3149802A patent/CA3149802A1/en active Pending
- 2020-08-07 MX MX2022001601A patent/MX2022001601A/es unknown
- 2020-08-07 KR KR1020227005865A patent/KR20220035954A/ko unknown
- 2020-08-07 EP EP20852914.9A patent/EP4015042A4/en active Pending
- 2020-08-07 JP JP2021506586A patent/JP6888180B1/ja active Active
- 2020-08-07 WO PCT/JP2020/030350 patent/WO2021029350A1/ja unknown
- 2020-08-07 AU AU2020327775A patent/AU2020327775B2/en active Active
- 2020-08-07 BR BR112022002269A patent/BR112022002269A2/pt unknown
- 2020-08-07 CN CN202080056973.0A patent/CN114206387A/zh active Pending
- 2020-12-17 US US17/125,591 patent/US11738006B2/en active Active
-
2022
- 2022-02-08 CL CL2022000330A patent/CL2022000330A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4015042A4 (en) | 2023-06-07 |
WO2021029350A1 (ja) | 2021-02-18 |
JPWO2021029350A1 (ja) | 2021-09-13 |
CN114206387A (zh) | 2022-03-18 |
US20210046052A1 (en) | 2021-02-18 |
KR20220035954A (ko) | 2022-03-22 |
TW202114661A (zh) | 2021-04-16 |
US10898470B1 (en) | 2021-01-26 |
CA3149802A1 (en) | 2021-02-18 |
US11738006B2 (en) | 2023-08-29 |
EP4015042A1 (en) | 2022-06-22 |
US20210220338A1 (en) | 2021-07-22 |
MX2022001601A (es) | 2022-03-11 |
AU2020327775B2 (en) | 2023-06-08 |
BR112022002269A2 (pt) | 2022-04-19 |
JP6888180B1 (ja) | 2021-06-16 |
AU2020327775A1 (en) | 2022-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022000330A1 (es) | Composición farmacéutica que contiene un agente antifúngico como ingrediente activo | |
UY36422A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
AR088383A1 (es) | Formulaciones de etanercept estabilizadas con combinaciones de azucares y polioles | |
AR057697A1 (es) | Composiciones de pulverizacion | |
DOP2016000267A (es) | Composiciones estables de yodo no en complejo y métodos de uso | |
UY37952A (es) | Formulaciones de un inhibidor de la quinasa trk macrocíclica | |
CL2020002252A1 (es) | Formulación oftálmica. | |
AR068544A1 (es) | Composiciones como medio de sello de heridas | |
BR112015025961A2 (pt) | composto, composição cosmética ou farmacêutica, e, uso de um composto | |
CO2021004221A2 (es) | Nanoemulsión antimicrobiana | |
ES2543957T3 (es) | Nueva composición farmacéutica para el tratamiento de infecciones fúngicas | |
BR112015022972A2 (pt) | composição farmacêutica de cloridrato de s-cetamina | |
UY39027A (es) | Uso de favipiravir en el tratamiento de la infección por coronavirus | |
AR077139A1 (es) | Composiciones farmaceuticas utiles para tratar el vch | |
AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
NI201300007A (es) | Un nuevo conjugado de granulocito colonia - estimulante factor (g -csf) con polietileno glicol. | |
AR114325A1 (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
AR114324A1 (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
UY36058A (es) | “dispositivo inhalador accionado por la respiración | |
AR108037A1 (es) | Uso de ésteres de un poliol alcoxilado para preparar una composición adyuvante para reducir la deriva en una formulación agroquímica, composición adyuvante obtenida, uso de la misma para preparar una formulación agroquímica y una mezcla de espray, y dicha formulación agroquímica y mezcla de espray | |
AR114323A1 (es) | Péptidos de la cadena b de la relaxina modificados y su uso terapéutico | |
CL2021001636A1 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
UY38345A (es) | Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g | |
CL2021000290A1 (es) | Un método de obtención de la forma de dosis líquida del medicamento edaravone, que es estable durante el almacenamiento, transporte y de uso conveniente | |
UY29403A1 (es) | Composiciones farmacéutica sólida que comprende telitromicina. |